A Phase 1 Study of PRT7732 in People With Solid Tumors

Full Title

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

Purpose

The purpose of this study is to find the best dose of PRT7732 that can be given safely in people with advanced solid tumors. The people in this study have solid tumors that have spread or came back after treatment. In addition, their cancers have a mutation (change) in a gene called SMARCA4.

PRT7732 helps break down a protein called SMARCA2, which allows tumor cells to grow and spread. Cancers that have loss of function in the SMARCA4 gene depend more on SMARCA2. By breaking down SMARCA2, cells with loss of function in SMARCA4 cannot rely on SMARCA2 and will die. PRT7732 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have a solid tumor that has spread or came back after treatment.
• Have recovered from the serious side effects of previous therapies before taking PRT7732.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call 646-888-4226.